Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY, BENCHMRK Study Teamsa.

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.

CLINICAL INFECTIOUS DISEASES 2010. 50(4): 605-612. Nº de citas: 172

[doi:10.1086/650002]

Navas Elorza E, Moreno Guillén S.

Tuberculosis multirresistente y extremadamente resistente.

Revista española de sanidad penitenciaria 2010. 12(3): 91-98.

[doi:10.4321/S1575-06202010000300005]

Poveda E, Anta L, Blanco JL, Pérez-Elías MJ, García F, Leal M, Ribera E, Gutiérrez F, Soriano V, de Mendoza C.

Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database.

AIDS 2010. 24(3): 469-471. Nº de citas: 13

[doi:10.1097/QAD.0b013e328331a4b8]

Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casbona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Pérez-Hoyos S, García de Olalla P, Hernán MA.

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.

AIDS 2010. 24(1): 123-137. Nº de citas: 287

[doi:10.1097/QAD.0b013e3283324283]

Fortún J.

LETTER TO THE EDITOR: Response to the Letter by Dr. Julio Collazos.

The open respiratory medicine journal 2010. 4: 17-17.

[doi:10.2174/1874306401004010017]

Moreno S, Mocroft A, Monforte Ad.

Medical and societal consequences of late presentation

ANTIVIRAL THERAPY 2010. 15(1): 9-15. Nº de citas: 56

[doi:10.3851/IMP1523]

Antinori A, Johnson M, Moreno S, Yazdanpanah Y, Rockstroh JK.

Report of a European Working Group on late presentation with HIV infection: recommendations and regional variation

ANTIVIRAL THERAPY 2010. 15(1): 31-35. Nº de citas: 23

[doi:10.3851/IMP1525]

Ghosn J, Carosi G, Moreno S, Pokrovsky V, Lazzarin A, Pialoux G, Sanz-Moreno J, Balogh A, Vandeloise E, Biguenet S, Leleu G, Delfraissy JF.

Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen

ANTIVIRAL THERAPY 2010. 15(7): 993-1002. Nº de citas: 33

[doi:10.3851/IMP1666]

Garriga C, Pérez-Elías MJ, Delgado R, Ruiz L, Pérez-Alvarez L, Pumarola T, López-Lirola A, González-García J, Menéndez-Arias L.

HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with virological failure to nucleoside drug combinations.

The Journal of antimicrobial chemotherapy 2009. 64(2): 251-258. Nº de citas: 11

[doi:10.1093/jac/dkp200]

Pérez Cachafeiro S, Del Amo J, Iribarren JA, Salavert Lleti M, Gutiérrez F, Moreno A, Labarga P, Pineda JA, Vidal F, Berenguer J, Moreno S.

Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006.

CLINICAL INFECTIOUS DISEASES 2009. 48(10): 1467-1470. Nº de citas: 52

[doi:10.1086/598333]

Sobrino-Vegas P, García-San Miguel L, Caro-Murillo AM, Miró JM, Viciana P, Tural C, Saumoy M, Santos I, Sola J, del Amo J, Moreno S, CoRIS.

Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality.

CURRENT HIV RESEARCH 2009. 7(2): 224-230. Nº de citas: 88

[doi:10.2174/157016209787581535]

de Mendoza C, Anta L, García F, Pérez-Elías MJ, Gutiérrez F, Llibre JM, Menéndez-Arias L, Dalmau D, Soriano V.

HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines.

AIDS REVIEWS 2009. 11(1): 39-51. Nº de citas: 17

González-Nieto D, Gómez-Hernández JM, Larrosa B, Gutiérrez C, Muñoz MD, Fasciani I, O'Brien J, Zappalà A, Cicirata F, Barrio LC.

Regulation of neuronal connexin-36 channels by pH

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2008. 105(44): 17169-17174. Nº de citas: 61

[doi:10.1073/pnas.0804189105]

Hernández-Novoa B, Antela A, Gutiérrez C, Pérez-Molina JA, Pérez-Elías MJ, Dronda F, Moreno A, Casado JL, Page C, Pumares M, Galán JC, Moreno S.

Effect of food on the antiviral activity of didanosine enteric-coated capsules: a pilot comparative study.

HIV MEDICINE 2008. 9(4): 187-191. Nº de citas: 5

[doi:10.1111/j.1468-1293.2008.00543.x]

Pérez-Elías MJ, Moreno A, Moreno S, López D, Antela A, Casado JL, Dronda F, Gutiérrez C, Quereda C, Navas E, Abraira V, Rodríguez MA.

Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults.

HIV CLINICAL TRIALS 2005. 6(6): 312-319. Nº de citas: 10

[doi:10.1310/B3NK-V5XQ-6VX9-5DEK]

Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V.

Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.

JOURNAL OF MEDICAL VIROLOGY 2005. 77(1): 23-28. Nº de citas: 19

[doi:10.1002/jmv.20395]

Pérez-Elías MJ, Moreno S, Gutiérrez C, López D, Abraira V, Moreno A, Dronda F, Casado JL, Antela A, Rodríguez MA.

High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir.

AIDS 2005. 19(7): 695-698. Nº de citas: 21

[doi:10.1097/01.aids.0000166092.39317.42]

Domínguez-Berjón MF, Pichiule-Castañeda M, García-Riolobos MC, Esteban-Vasallo MD, Arenas-González SM, Morán-Arribas M, Verdejo-Ortés J, Zoni AC, Álvarez-Castillo MC, Astray J, others members of the ESTVIH group.

A feasibility study for 3 strategies promoting HIV testing in primary health care in Madrid, Spain (ESTVIH project).

JOURNAL OF EVALUATION IN CLINICAL PRACTICE . : .

[doi:10.1111/jep.12813]